Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 8/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195854 | 0.84 | PDE4A (0.47) | PDE4APDE4CPDE4DNCEH1EPAS1 | |
| SCHEMBL1195899 | 0.83 | HSD11B1 (0.45) | PDE4APDE4CPDE4DEPAS1PTPN1 | |
| SCHEMBL6812108 | 0.80 | SLC6A2 (0.44) | PDE4APDE4CPDE4DPTPN1CA1 | |
| SCHEMBL7245579 | 0.79 | CYP2A6 (0.38) | EPAS1PTPN1CA1CA2CA9 | |
| SCHEMBL6704839 | 0.79 | NCEH1 (0.39) | NCEH1EPAS1CA1CA2HSD11B1 | |
| SCHEMBL5728291 | 0.79 | EPAS1 (0.45) | PDE4APDE4CPDE4DEPAS1VEGFA | |
| SCHEMBL21723413 | 0.79 | SLC22A12 (0.41) | PDE4APDE4CPDE4DEPAS1VEGFA | |
| SCHEMBL31245789 | 0.79 | SLC22A12 (0.41) | PDE4APDE4CPDE4DEPAS1VEGFA | |
| SCHEMBL16179448 | 0.77 | MRGPRX4 (0.42) | PDE4APDE4CPDE4DEPAS1VEGFA | |
| SCHEMBL1738137 | 0.77 | TRPV4 (0.54) | PDE4APDE4CPDE4DEPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010695-A1 | Diphosphines, preparation and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-01-11 | — | — | US | disclosed |
| US-20040102649-A1 | Water soluble chiral diphoshpines | RHODIA CHIMIE (FR) | 2004-05-27 | — | — | US | disclosed |
| US-20030225297-A1 | Process for preparing chiral diphosphines | RHODIA CHIMIE | 2003-12-04 | — | — | US | disclosed |
| US-6646106-B1 | Polymerizing chiral diphosphine having a C2 axis of symmetry, with one or several polymerizable monomers, said chiral diphosphine consisting of a chiral body bearing two identical functional groups | RHODIA CHIMIE (FR) | 2003-11-11 | — | — | US | disclosed |
| US-6610875-B1 | Forming bidentate ligands ofr assymetric catalysts; bromina-ting diaryldiol; esterifying with sulfonic acid; substituting cyano for bromine groups; coupling with a dicyclophosphine | RHODIA CHIMIE (FR) | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102649-A1 | Water soluble chiral diphoshpines | ADRA1B, ADRB1, ADRA1A | PDE4A 1788/4885PDE4C 2115/4885PDE4D 2815/4885 |
| US-20070010695-A1 | Diphosphines, preparation and uses thereof | MPI, ITPA, DCPS | PDE4A 1240/4885PDE4C 768/4885PDE4D 1284/4885 |
| US-20030225297-A1 | Process for preparing chiral diphosphines | CYP1A1, NR5A1, AR | PDE4A 1077/4885PDE4C 1500/4885PDE4D 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.